Analysts' ratings for Arcturus Therapeutics (NASDAQ:ARCT) over the last quarter vary from bullish to bearish, as provided by 8 analysts. The table below offers a condensed view of their recent ...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and ...

Good day, everyone, and welcome to today's Arcturus Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later ...

Across the recent three months, 5 analysts have shared their insights on Arcturus Therapeutics ARCT, expressing a variety of opinions spanning from bullish to bearish. The table below summarizes ...

BTIG raised the firm’s price target on Arcturus Therapeutics (ARCT) to $48 from $41 and keeps a Buy rating on the shares. The Kostaive COVID-19 vaccine approval in Europe was reassuring for a ...

Despite a dip in revenue, Arcturus Therapeutics Holdings Inc (ARCT) focuses on innovation and strategic partnerships to bolster its pipeline and financial position. SAN DIEGO (AP) — Arcturus ...

Arcturus Therapeutics and CSL's COVID-19 vaccine Kostaive has been approved for marketing in the EU, becoming the first based on self-amplifying mRNA (sa-mRNA) to clear that threshold. While ...

“KOSTAIVE and sa-mRNA technology signify a major advancement in vaccine innovation, providing the potential for broader and more enduring protection,” said Joseph Payne, CEO of Arcturus. “This ...